Want to see IVF full AI Analyst Report?
Top Page
INVO Fertility
(NASDAQ:IVF)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.61
▼(-41.07% Downside)
Action:Downgraded
Date:10/14/26
The score is held down primarily by continued operating losses and ongoing cash burn despite strong revenue growth and an improved balance sheet. Technical signals are also notably bearish with the stock trading well below key moving averages and negative MACD. Recent financing improves liquidity flexibility but adds dilution risk, and valuation metrics provide limited support due to negative earnings and no dividend yield data.
Positive Factors
Revenue Growth
Revenue expansion from approximately $0.8 million in 2022 to $7.5 million on a TTM basis indicates stronger commercial traction and broader patient-service activity. If maintained, this growth can improve operating leverage, support reinvestment, and strengthen the company’s position in fertility services.
Negative Factors
Persistent Operating Losses
Persistent operating and net losses show that current revenue and gross profit are not yet sufficient to cover the company’s broader cost base. Continued losses can consume financial resources, delay self-funded growth, and make eventual profitability dependent on substantial operating improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue expansion from approximately $0.8 million in 2022 to $7.5 million on a TTM basis indicates stronger commercial traction and broader patient-service activity. If maintained, this growth can improve operating leverage, support reinvestment, and strengthen the company’s position in fertility services.
Read all positive factors
INVO Fertility (IVF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.72M
Dividend YieldN/A
Average Volume (3M)132.24K
Price to Earnings (P/E)―
Beta (1Y)0.34
Revenue Growth13.76%
EPS Growth99.18%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-30.68
Shares Outstanding4,771,364
10 Day Avg. Volume113,435
30 Day Avg. Volume132,236
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.06
Price to Sales (P/S)0.06
P/FCF Ratio-0.06
Enterprise Value/Market Cap2.03
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit2.20
Enterprise Value/Ebitda-0.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.9
Revenue Forecast (FY)$10.42M
INVO Fertility Business Overview & Revenue Model
Company Description
INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was establi...
How the Company Makes Money
INVO Fertility generates revenue primarily from providing fertility treatment services to patients through its clinical operations (e.g., IVF-related care and associated fertility services), where patients or payors pay for treatment cycles and re...
INVO Fertility Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.53M | 6.84M | 6.53M | 3.02M | 822.20K | 4.16M |
| Gross Profit | 2.51M | 2.53M | 2.87M | 1.09M | -28.57K | 4.02M |
| EBITDA | -6.10M | -3.51M | -7.14M | -6.88M | -10.75M | -5.22M |
| Net Income | -5.29M | -23.32M | -9.10M | -8.03M | -10.89M | -6.65M |
Balance Sheet | ||||||
| Total Assets | 25.83M | 20.22M | 46.45M | 18.51M | 3.71M | 10.47M |
| Cash, Cash Equivalents and Short-Term Investments | 3.73M | 2.08M | 741.40K | 232.42K | 90.14K | 5.68M |
| Total Debt | 3.92M | 3.40M | 9.90M | 6.30M | 2.27M | 2.12M |
| Total Liabilities | 9.34M | 13.00M | 33.70M | 17.61M | 4.69M | 3.16M |
| Stockholders Equity | 16.49M | 7.22M | 12.75M | 892.83K | -977.61K | 7.31M |
Cash Flow | ||||||
| Free Cash Flow | -4.81M | -7.06M | -3.16M | -5.20M | -6.62M | -6.48M |
| Operating Cash Flow | -4.77M | -7.01M | -2.97M | -4.76M | -6.60M | -6.03M |
| Investing Cash Flow | -2.93M | -2.75M | 363.89K | -2.49M | -81.22K | -2.15M |
| Financing Cash Flow | 10.88M | 11.10M | 3.12M | 7.39M | 1.09M | 3.77M |
INVO Fertility Technical Analysis
Negative
1.03
Price Trends
0.90
Negative
1.09
Negative
2.39
Negative
Market Momentum
-0.11
Positive
27.80
Positive
16.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVF, the sentiment is Negative. The current price of 1.03 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.90, and below the 200-day MA of 2.39, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 27.80 is Positive, neither overbought nor oversold. The STOCH value of 16.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVF.
INVO Fertility Risk Analysis
INVO Fertility disclosed 60 risk factors in its most recent earnings report. INVO Fertility reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
INVO Fertility Peers Comparison
UnderperformOutperform
Sector (51)
IVF
INVO Fertility
0.57
-20.84
-97.34%
NIVF
NewGenIvf Group
1.46
-20,596.31
-99.99%
INVO Fertility Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
INVO Fertility Announces Equity Financing and Capital Commitment
Positive
Aug 28, 2026
INVO Fertility, Inc. has published an investor presentation on its website and plans to use it at the H.C. Wainwright 28th Annual Global Investment Conference scheduled for September 14–16, 2026. The materials outline the company’s cur...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
INVO Fertility Expands Authorized Shares to Support Financing
Neutral
Jul 24, 2026
On January 23, 2026, INVO Fertility held its annual meeting of stockholders, where shareholders re-elected all five directors and ratified Withum Smith+Brown, PC as the company’s independent auditor for the 2026 fiscal year. Investors also a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.